Using the Sun Pharma–Organon transaction as a lens, this carousel explores how overseas acquisitions are evaluated under the FEMA ODI framework — from reverse triangular mergers and FC limits to reporting obligations and structuring considerations.
A practical perspective on balancing global expansion with FEMA compliance.
Click here to view the details!